| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants (NCT03128489) | GlaxoSmithKline | 2017-12-01 |
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02853929) | GlaxoSmithKline | 2016-09-19 |
| Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02422264) | GlaxoSmithKline | 2016-01-22 |
| Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (NCT02569879) | GlaxoSmithKline | 2015-10-01 |
| Duration of Protection: GSK DTaP Vaccines (NCT02447978) | GlaxoSmithKline | 2015-02-01 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants (NCT02096263) | GlaxoSmithKline | 2014-04-16 |
| Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children (NCT01988857) | GlaxoSmithKline | 2014-02-22 |
| Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants (NCT01890850) | GlaxoSmithKline | 2013-07-01 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (NCT01738477) | GlaxoSmithKline | 2013-01-31 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (NCT01577732) | GlaxoSmithKline | 2012-12-08 |
| Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea (NCT01568060) | GlaxoSmithKline | 2012-05-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine (NCT01353703) | GlaxoSmithKline | 2012-04-16 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01453998) | GlaxoSmithKline | 2011-10-14 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (NCT01449812) | GlaxoSmithKline | 2011-10-01 |
| Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents (NCT01362322) | GlaxoSmithKline | 2011-07-01 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (NCT01358825) | GlaxoSmithKline | 2011-05-30 |
| Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults (NCT01323959) | GlaxoSmithKline | 2011-04-01 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (NCT01309646) | GlaxoSmithKline | 2011-03-04 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01248884) | GlaxoSmithKline | 2010-12-09 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (NCT01171989) | GlaxoSmithKline | 2010-08-18 |
| Evaluation of Boostrix™10 Years After Previous Booster Vaccination (NCT01147900) | GlaxoSmithKline | 2010-06-15 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (NCT01090453) | GlaxoSmithKline | 2010-05-17 |
| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine (NCT01086423) | GlaxoSmithKline | 2010-03-01 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) (NCT00964028) | GlaxoSmithKline | 2009-12-01 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (NCT00970307) | GlaxoSmithKline | 2009-08-13 |
| Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (NCT00871000) | GlaxoSmithKline | 2009-04-01 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. (NCT00871741) | GlaxoSmithKline | 2009-04-01 |
| Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years (NCT00871117) | GlaxoSmithKline | 2009-03-31 |
| Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. (NCT00835237) | GlaxoSmithKline | 2009-02-17 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants (NCT00753649) | GlaxoSmithKline | 2008-09-23 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children (NCT00696423) | GlaxoSmithKline | 2008-06-07 |
| Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children (NCT00611559) | GlaxoSmithKline | 2008-02-14 |
| Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine (NCT00635128) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (NCT00627458) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. (NCT00610168) | GlaxoSmithKline | 2008-01-01 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 (NCT00548171) | GlaxoSmithKline | 2007-11-05 |
| Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 (NCT00489970) | GlaxoSmithKline | 2007-06-01 |
| Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (NCT00463437) | GlaxoSmithKline | 2007-04-25 |
| Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine (NCT00452686) | GlaxoSmithKline | 2007-03-01 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. (NCT00406562) | GlaxoSmithKline | 2007-01-01 |
| Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults (NCT00385255) | GlaxoSmithKline | 2006-10-23 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (NCT00376779) | GlaxoSmithKline | 2006-10-01 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age (NCT00379977) | GlaxoSmithKline | 2006-09-01 |
| Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years (NCT00346073) | GlaxoSmithKline | 2006-07-13 |
| Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants (NCT00320463) | GlaxoSmithKline | 2006-04-01 |
| Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine (NCT00297856) | GlaxoSmithKline | 2006-03-01 |
| US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease (NCT00282295) | GlaxoSmithKline | 2006-01-25 |
| Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants (NCT00290342) | GlaxoSmithKline | 2006-01-01 |
| Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules (NCT00316147) | GlaxoSmithKline | 2005-12-01 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 (NCT00307567) | GlaxoSmithKline | 2005-11-01 |
| Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines (NCT00148941) | GlaxoSmithKline | 2005-01-06 |
| Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants (NCT00325156) | GlaxoSmithKline | 2004-11-02 |
| Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine (NCT00325143) | GlaxoSmithKline | 2003-12-01 |
| Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. (NCT00263679) | GlaxoSmithKline | 2003-11-01 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (NCT01457547) | GlaxoSmithKline | 2003-10-01 |
| Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (NCT00352963) | GlaxoSmithKline | 2003-09-30 |
| Post Market Surveillance for Infanrix™ (NCT00908115) | GlaxoSmithKline | 2003-08-01 |
| Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines. (NCT00544271) | GlaxoSmithKline | 2003-05-01 |
| Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) (NCT01294605) | GlaxoSmithKline | 2003-04-01 |
| Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine (NCT00146835) | GlaxoSmithKline | 2003-04-01 |
| A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine (NCT00109330) | GlaxoSmithKline | 2002-11-01 |
| Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety (NCT00263692) | GlaxoSmithKline | 2002-11-01 |
| Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® (NCT01277705) | GlaxoSmithKline | 2002-01-01 |
| Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants (NCT00879827) | GlaxoSmithKline | 2000-09-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (NCT01457560) | GlaxoSmithKline | 2000-02-01 |